Regimen Reference Order – PACLitaxel desensitization

PACLitaxel desensitization protocol is prescribed in combination with a PACLitaxel-based protocol To order this therapy in ARIA, refer to ADDITIONAL INFORMATION

Planned Course: Refer to prescribed PACLitaxel-based protocol

Indication for Use: Eligible patients with previous hypersensitivity reactions to PACLitaxel

Alert: Desensitization protocol

PACLitaxel:

- PACLitaxel is prepared in 3 separate bags with a total volume of 250 mL in each bag
- IV tubing is primed with PACLitaxel (Cytotoxic)
- PACLitaxel is administered slowly following specified rate increases. PACLitaxel infusion takes approximately 5.75 hours to complete

CVAD: At Provider's Discretion

Blood work requirements:

* Refer to prescribed PACLitaxel-based protocol

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements					
Dru	ag	Dose	CCMB Administration Guideline		
Refer to prescribed PACLitaxel-based protocol					

Establish primary solution 500 mL of: normal saline				
Drug	Dose	CCMB Administration Guideline		
	•	used in place of PACLitaxel by standard administration in the administration of the prescribed PACLitaxel-based protocol		
amotidine	40 mg	Orally <u>1 hour</u> prior to PACLitaxel		
montelukast	10 mg	Orally <u>1 hour</u> prior to PACLitaxel		
cetirizine	20 mg	Orally <u>1 hour</u> prior to PACLitaxel		
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel		
		*Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion		

PACLitaxel	1/100 th (1%) of dose (BAG 1)	IV in normal saline 250 mL following the administration rates below:
		Step 1: 2.5 mL/hour for 15 minutes, then
		Step 2: 5 mL/hour for 15 minutes, then
		Step 3: 10 mL/hour for 15 minutes, then
		Step 4: 20 mL/hour for 15 minutes
		Once step 4 is complete, discard remainder of bag and proceed immediately to BAG 2
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Alert: Pharmacy to ensure final volume in bag = 250 mL
		*Nursing Alert: IV tubing is primed with PACLitaxel
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior
		to administration of PACLitaxel to evenly distribute the drug
	1/10 th (10%) of dose (BAG 2)	IV in normal saline 250 mL following the administration rates below:
	(BAG 2)	Step 5: 5 mL/hour for 15 minutes, then
		Step 6: 10 mL/hour for 15 minutes, then
		Step 7: 20 mL/hour for 15 minutes, then
		Step 8: 40 mL/hour for 15 minutes
		Once step 8 is complete, discard remainder of bag and proceed immediately to BAG 3
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Alert: Pharmacy to ensure final volume in bag = 250 mL
		*Nursing Alert: IV tubing is primed with PACLitaxel
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug
	99.2% of dose (BAG 3)	IV in normal saline 250 mL following the administration rates below:
		Step 9: 10 mL/hour for 15 minutes, then
		Step 10: 20 mL/hour for 15 minutes, then
		Step 11: 40 mL/hour for 15 minutes, then
		Step 12: 80 mL/hour until infusion is complete
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Alert: Pharmacy to ensure final volume in bag = 250 mL
		*Nursing Alert: IV tubing is primed with PACLitaxel
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'



REQUIRED MONITORING

All Cycles

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not
- · Refer to the prescribed PACLitaxel-based protocol for additional monitoring

Recommended Support Medications						
Drug	Dose	CCMB Administration Guideline				
Refer to prescribed PACLitaxel-based protocol						

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- · Refer to the prescribed PACLitaxel-based protocol for additional discharge instructions
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Oncologist must write first prescription of PACLitaxel desensitization protocol
- Once the patient requires PACLitaxel desensitization protocol, all subsequent PACLitaxel doses <u>must</u> be given using PACLitaxel desensitization protocol
- · Refer to the prescribed PACLitaxel-based protocol for additional PACLitaxel information
- <u>ARIA ordering</u>: Support protocols are available under <u>PACLitaxel 80 mg/m2</u> and <u>PACLitaxel 175 mg/m2</u> in the "Desensitization" folder
- Due to the duration of treatment, administration site restrictions may be in place for PACLitaxel desensitization

